F-star Appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA
F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer.
Darlene Deptula-Hicks joins F-star from Northern Biologics, Inc., a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody therapeutics in oncology. Previously, Darlene held CFO positions across both private and publicly listed US companies, including Pieris Pharmaceuticals Inc., Microline Surgical Inc. and T2 Biosystems Inc. She brings to F-star a proven track record of finance strategy and leadership, capital raising, industry knowledge and the ability to build strong strategic partnerships.
Darlene Deptula-Hicks, CFO of F-star, said: “It is a very exciting time to be joining F-star given its evolution to a fully-fledged clinical-stage, international business. The company’s pipeline of promising bispecific antibodies has the potential to address the growing need for, and commercial opportunity from, more efficacious therapies for cancer patients. I am excited to join the management team of this next-generation immunotherapy business.”
Eliot Forster, CEO of F-star, said: “We believe Darlene’s strong commercial and capital markets experience from within the life sciences sector will play a critical role in our transition and I’m delighted that she has joined the company. Tolga’s expertise and company knowledge continues to be vital to our success as we work towards realising our ambition to bring new drugs to cancer patients as quickly as we can.”
To support F-star’s international expansion strategy, the company has also established US operations based in Cambridge, MA. Research operations will continue at the company’s site in Cambridge, UK, while the US office will support the growth of F-star’s in-house financial, clinical and regulatory activities.
F-star has also appointed Lindsey Trickett as Vice President of Investor Relations and Communications. Lindsey brings with her a wealth of experience in investor relations and antibody drug development. She joins F-star from Intellia Therapeutics, Inc., where she served as a Vice President of Investor Relations. Previously, Lindsey held senior IR and strategic marketing positions at AstraZeneca plc and spent over a decade in roles of increasing responsibility at MedImmune, LLC/AstraZeneca plc.
Both Darlene and Lindsey will be based out of F-star’s US office.
- ENDS -
About F-star Therapeutics Ltd
F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumour immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is generating first- and best-in-class drug candidates with monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for cancer patients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005498/en/
Contact information
For investor enquiries:
Lindsey Trickett
VP
Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com
Consilium
Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel:
+44 (0)20 3709 5700
E-mail:
F-star@consilium-comms.com
For
media enquiries
Pierre Peotta
Communications Manager
+44
(0)1223 948 094
+44 (0)7392 080 279
pierre.peotta@f-star.com
US
Catherine
London, US President
Tel: +1 917-763-2709
E-mail: F-star@consilium-comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WEYTEC and Raytheon Team Up to Enhance Air Traffic Management Technology21.10.2019 19:23:00 EEST | Press release
WEY Technology (WEYTEC) and Raytheon Company (NYSE: RTN) have signed a teaming agreement to co-develop the next-generation air traffic controller workplaces called Multi-platform ATC Re-hosting Solution, or MARS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005591/en/ ATC Workplaces of the Future (Photo: Business Wire) Today in the U.S., air traffic controllers use Raytheon's Standard Terminal Automation Replacement System, or STARS, to provide safe and efficient aircraft spacing and sequencing guidance for more than 40,000 departing and arriving aircraft daily at both civilian and military airports. WEYTEC brings smart tech to airport command and control centers around the world through the transmission, control, distribution and display of real-time data critical to efficient flight operations. "Our integrated KVM solutions are autonomous, scalable, and IP-based, which makes them ideal for complex multiscreen workp
Tommy Hilfiger Appoints Michael Scheiner as Global Chief Marketing Officer21.10.2019 18:15:00 EEST | Press release
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], is pleased to announce the appointment of Michael Scheiner as Chief Marketing Officer, Tommy Hilfiger Global, effective October 28, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005511/en/ Michael Scheiner, Chief Marketing Officer, Tommy Hilfiger Global (Photo: Business Wire) Michael has amassed over 15 years of experience at global brands. He joins Tommy Hilfiger from Hollister Co., where he served as SVP, Global Marketing. His work helped to move Hollister into the top 5 brands among teens in Piper Jaffray’s Fall 2019 Taking Stock survey, and supported Hollister’s recognition as a Top Omni-Channel retailer. Michael will utilize his passion and experience to lead TOMMY HILFIGER into a new era of innovative marketing strategies – particularly across digital and experiential platforms – to reach and engage the next generation of consumers. “As one of the wo
Workiva Named Large Software Company of the Year by International Business Awards®21.10.2019 16:03:00 EEST | Press release
Workiva (NYSE:WK), provider of the world’s leading connected reporting and compliance platform, has won a Gold Stevie® Award for Company of the Year in the large software company category in The 16th Annual International Business Awards®. The awards were presented at a gala ceremony in Vienna, Austria on October 19. “Workiva is honored to be recognized globally with a Gold Stevie Award,” said Marty Vanderploeg, CEO of Workiva. “We give our employees the freedom and resources they need – backed by our culture of collaboration and inclusion – to help our customers around the world build trust with connected reporting." The International Business Awards are the world’s premier business awards program. A record total of more than 4,000 nominations from organizations of various sizes and industries in 74 nations and territories were submitted this year for consideration in a wide range of categories. More than 250 executives worldwide served as Stevie Awards judges from May through August.
Mavenir Demonstrates Automated Deployment of Cloud-Native 5G Core at MWC LA21.10.2019 16:00:00 EEST | Press release
Mobile World Congress: Mavenir, a US-based Network Software Provider, and the industry's only end-to-end cloud-native vendor for CSPs, announced today its 5G Core platform, which includes a comprehensive set of 5G core functions on a containerized cloud-native platform. The decomposition of functions into these modular units provides the operators the flexibility to scale them independently; scalability and flexibility that wasn’t possible with 4G EPC. Mavenir has invested heavily in developing the 5G Core solution from the ground-up on cloud-native principles that can still be retrofitted on EPCs. The solution encompasses all the major 5G core elements, such as AMF, SMF, UPF, NRF, UDSF, PCF, UDM, UDR, NSSF, AUSF, BSF, N3IWF, SCP, SEPP, and SMSF. All these functions are implemented as micro-services in containers. In addition, Mavenir is also building remaining 5G core functions, NEF, 5G-EIR, NWDAF etc. The Mavenir 5G Core also combines 4G EPC functionality and offers a ‘Converged Mobi
ResMed Introduces AirFit N30, World’s First Tube-Down Nasal Cradle CPAP Mask21.10.2019 16:00:00 EEST | Press release
ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit N30, the world’s first tube-down nasal cradle CPAP mask with a front-facing tube – a brand-new option for sleep apnea treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005138/en/ ResMed AirFit N30, tube-down nasal cradle CPAP mask (Photo: Business Wire) ResMed’s lightest mask yet, AirFit N30 features an adjustable elastic headgear, plus a nasal cradle cushion that sits under the nasal bridge, eliminating soreness in that area. The mask’s curved cushion is designed to provide a secure seal regardless of how the wearer sleeps or moves. Together, these innovations help make starting and staying on CPAP therapy easier than ever for more of the 936 million people worldwide living with sleep apnea. “AirFit N30 is about ease of use, helping people ease into therapy and addressing the most common pain points for longtime users,” said Jim Hollingshead, president of R
STELARA® (ustekinumab) Data Demonstrate Long-term Efficacy and Safety Results in Adults With Moderately to Severely Active Ulcerative Colitis in Phase 3 Extension Trial21.10.2019 15:12:00 EEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of the Phase 3 UNIFI study, demonstrating the efficacy and safety of ustekinumab through two years of treatment in adults with moderately to severely active ulcerative colitis (UC). These data are being presented today as a late-breaking data presentation (LB01) at the 27th UEGW congress.1 These data include 399 participants who were in clinical response eight weeks after receiving a single intravenous (IV) induction dose of ustekinumab and who were then randomised to receive ustekinumab subcutaneous (SC) 90 mg injections every 12 weeks (q12w), ustekinumab SC 90 mg injections every 8 weeks (q8w), or placebo, and who were treated in the long-term extension.1 Results showed that the majority of patients were able to sustain remission through to week 92 as assessed by symptomatic remission. The percentage of patients receiving ustekinumab SC who were in symptomatic remi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom